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Pleural effusionAbstract Background: The undiagnosed pleural effusions are an important clinical problem so
scientists spent much effort and time in searching for a new parameter to help in the diagnosis
of pleural effusions. Vascular endothelial growth factor (VEGF) helps in differentiation between
malignant and inﬂammatory pleural effusions and might play an important role in tumor progres-
sion and the formation of malignant effusions.
Aim of the work: To determine the level of pleural ﬂuid VEGF in order to evaluate its value as a
marker for differentiation between different types of pleural effusions.
Subjects and methods: The present study was conducted on 73 patients with pleural effusion,
admitted to Kasr Elaini Hospital (Chest Department) during the period from August 2011 to
October 2012, after having their written consent. All patients were subjected basically to full history
taking, thorough clinical examination, routine laboratory investigations, plain chest radiography
thoracentesis. Medical thoracoscopy was carried out for cases with undiagnosed exudative pleural
effusion (n= 46).
Results: Pleural ﬂuidVEGF, andpleural ﬂuidVEGF/serumVEGFratio both are highest inmalig-
nant pleural effusion with statistically high signiﬁcance (p< 0.001), followed by infectious effusion
then tuberculous one.UsingROCcurve analysis, the cut-off used forVEGF in pleural ﬂuid in discrim-
inating malignant from other groups is 1800 pg/ml with sensitivity of 95% and speciﬁcity of 96%.
Conclusion: VEGF is highest in malignant pleural effusion. The differential diagnosis of effusions
might be further improved by including vascular endothelial growth factor concentrations into the
diagnostic armentarium available to the clinician.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Pleural effusion is an accumulation of ﬂuid in the pleural
space, as a result of excessive transudation or exudation from
the pleural surface. It is a sign for many diseases and not a
diagnosis, so correct diagnosis remains a major challenge to
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tant clinical problem so scientists spent much effort and time in
searching for a new parameter to help in the diagnosis of etiol-
ogy of different types of pleural effusions [2].
Vascular endothelial growth factor (VEGF) is a multifunc-
tional cytokine that increases microvascular permeability and
induces endothelial cell growth and angiogenesis. It was
reported that it enhances the activation and migration of
monocytes through the Fms-like tyrosine kinase (FLT)
receptor of VEGF. This cytokine also helps in differentiation
between malignant and inﬂammatory pleural effusions [3].
Maximum VEGF concentrations in malignant effusions
indicate abundant local release of VEGF within the pleural
cavity, which suggests that VEGF might play an important
role in tumor progression and the formation of malignant
effusions [4].
The aim of the present study is to determine the level of
serum and pleural ﬂuid vascular endothelial growth factor in
order to evaluate its value as a marker for differentiation
between different types of pleural effusions.Table 1 The Study groups.
Patients Number Percent %
Group I (Transudative pleural eﬀusion) 10 13.7
Group IIa (Malignant pleural eﬀusion) 35 47.9
Group IIb (Tuberculous pleural eﬀusion) 11 15.1
Group IIc (Infectious pleural eﬀusion) 17 23.3
Total 73 100.0
Controls 13 100.0Subjects and methods
The present study was conducted on 73 patients with pleural
effusion of different etiologies, admitted to Kasr El-Aini
Hospital (Chest Department) during the period from August
2011 to October 2012, after having their written consent prior
to participation in the study.
These patients were 41 males and 32 females with age ran-
ged from 18 to 70 years. The etiology of exudative pleural effu-
sion was established by deﬁnite pathological diagnosis of
pleural ﬂuid and/or biopsy. The patients were classiﬁed into
two groups, according to the type of effusion whether transu-
date or exudate.
All patients were subjected basically to full history taking,
thorough clinical examination, routine laboratory investiga-
tions, plain chest radiography (postero-anterior and lateral
views) and thoracentesis. Medical thoracoscopy was carried
out for cases with undiagnosed exudative pleural effusion
(n= 46). The pleural ﬂuid obtained was examined as regards:
Gross appearance and nature of the ﬂuid, total protein in
gm/dl was measured on synchron CX5 auto analyzer, Lactate
dehydrogenase enzyme (LDH) was measured in IU/L, adeno-
sine deaminease enzyme (ADA) was measured in IU/L, total
and differential cell count of the pleural ﬂuid, bacteriological
examination by: culture and sensitivity & Zeil-Neelsen stain
for acid fast bacilli (AFB), cytological examination for
malignant cells. Levels of pleural ﬂuid vascular endothelial
growth factor (VEGF) in pg/ml usingELISA for humanVEGF,
using the commercially available Orgenium Laboratories‘
vascular endothelial growth factor (VEGF) ELISA. Venous
blood samples were obtained simultaneously to measure pro-
tein, glucose, LDH, ADA & VEGF using the commercially
available Orgenium Laboratories’ vascular endothelial growth
factor (VEGF) ELISA.
For determination of the etiology of pleural effusion
further different relevant investigations and procedures were
performed whenever needed: e.g. complete blood picture
(CBC), erythrocyte sedimentation rate (ESR), tuberculin test
by the Mantoux method, liver and kidney function tests, spu-
tum examination for AFB (ZN stain), sputum culture andsensitivity, abdominal ultrasonography, CT-chest, Echo-heart
and ﬁberoptic bronchoscopy.
The patients were classiﬁed into two groups, according to
the type of effusion whether transudate or exudate according
to Lights criteria [5].
Group I
This group included 10 cases with transudative pleural effu-
sion. They were 6 males (60%) and 4 females (40%), with
mean age of 60 ± 7.1 years.
Group II
This group included 63 cases with exudative pleural effusions,
35 males (55.6%) and 28 females (44.4), with mean age of
49.1 ± 15 years. Group II is further subdivided into malignant
pleural effusion, tuberculous pleural effusion and infectious
pleural effusion.Results
The present study was conducted on 73 patients with pleural
effusion of different etiologies. The etiology of exudative pleu-
ral effusion was established by deﬁnite pathological diagnosis
of pleural ﬂuid and/or biopsy (Tables 1 and 2).
Table 2 shows that cases with exudative pleural effusion
have higher mean ﬂuid VEGF (2109 ± 1338) than that of
cases with transudative pleural effusion (142 ± 28) and the
difference is statistically highly signiﬁcant (P< 0.01). And it
also shows that cases with exudative pleural effusion have
higher mean serum VEGF (325 ± 89) than that of cases with
transudative pleural effusion (170 ± 55) and the difference is
statistically highly signiﬁcant (P< 0.01) (Table 3).
Table 3 shows that the highest mean value of pleural ﬂuid
VEGF is among the malignant effusion group (3208 ±
609.52), followed by the infectious effusion group
(974.12 ± 217.98) followed by the tuberculous effusion group
(364.09 ± 27.73) (Table 4).
Table 4 shows that the difference in the mean value of ﬂuid
VEGF between the malignant effusion group and the tubercu-
lous group was highly signiﬁcant (p< 0.001) and difference
between the malignant group and the infectious effusion group
was also statistically highly signiﬁcant (p< 0.001). But the dif-
ference in the mean value of ﬂuid VEGF between the
infectious effusion group and the tuberculous group was statis-
tically insigniﬁcant (Fig. 1 & Table 5).
Table 5 shows that Group II patients (with
exudative pleural effusion) have higher serum VEGF mean
Table 2 Comparsion between the exudative group collectively and the transudative group.
Groups p-Value
Group II exudate Group I Transudate
Mean Std. Deviation Mean Std. Deviation
VEGF. ﬂuid 2109.12 1338.78 142.00 28.98 <0.001
VEGF. serum 325.11 89.004 170.90 55.90 <0.001
Table 3 Comparison between the levels of VEGF in pleural ﬂuid in the different exudative groups.
Group IIa (Malignant pl eﬀusion) Group IIb (Tuberculous pl eﬀusion) Group IIc (Infectious pl eﬀusion)
Mean ±SD Mean ±SD Mean ±SD
VEGF in pl ﬂuid pg/ml 3208.86 609.52 364.09 27.73 974.12 217.98
Table 4 Signiﬁcance of pleural ﬂuid VEGF in exudative groups.
p-Value
VEGF.ﬂuids Group IIA (Malignant pl eﬀusion) Group IIB (Tuberculous pl eﬀusion) <0.001
Group IIA (Malignant pl eﬀusion) Group I1C (Infectious pl eﬀusion) <0.001
Group IIB (Tuberculous pl eﬀusion) Group IIC (Infectious pl eﬀusion) 0.08
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and the differences are statistically highly signiﬁcant
(Table 6).
Table 6 shows that the patients with malignant pleural
effusion have the highest ratio (mean value 8.75 ± 1.54),
followed by the infectious effusion group (mean value
3.45 ± 0.77), while lowest values are observed in the groupFigure 1 Comparison between the levels of VEof tuberculous pleural effusion (mean value 1.66 ± 0.29)
(Table 7).
Table 7 shows that the difference in the ratio of VEGF
(pleural ﬂuid VEGF/serum VEGF) between the malignant
effusion group and the tuberculous group was highly signiﬁ-
cant (p< 0.001) and difference between the malignant group
and the infectious effusion group was also statistically highlyGF in pleural ﬂuid in the different groups.
Table 5 Comparison between the serum levels of VEGF in the different groups.
Groups p-Value
Group II (Exudative eﬀusion) Group I (Transudative eﬀusion)
Mean ±SD Mean ±SD
VEGF serum pg/ml 325.11 89.00 170.90 55.90 <0.01*
* Highly signiﬁcant.
Table 6 Comparison between the ratio of VEGF (pleural ﬂuid VEGF/serum VEGF) among the exudative group of effusion.
Study groups
Group IIa (Malignant pl eﬀusion) Group IIb (Tuberculous pl eﬀusion) Group IIb (Infectious pl eﬀusion)
Mean ±SD Mean ±SD Mean ±SD
VEGF ﬂuid/serum ratio 8.75 1.54 1.66 0.29 3.45 0.77
Table 7 Signiﬁcance of the ratio of VEGF (pleural ﬂuid VEGF/serum VEGF) among the exudative group of effusion.
p-Value
VEGF ﬂuids Group IIA (Malignat pl eﬀusion) Group IIB (Tuberculous pl eﬀusion) <0.001
Group IIA (Malignat pl eﬀusion) Group I1C (Infectious pl eﬀusion) <0.001
Group IIB (Tuberculous pl eﬀusion) Group IIC (Infectious pl eﬀusion) 0.03
Figure 2 Results of ROC curve analysis for ﬂuid VEGF in
diagnosis of malignant pleural effusion.
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tious effusion group and the tuberculous group was statisti-
cally insigniﬁcant.
ROC curve analysis
ROC (Receiver Operating Characteristic) curve was
constructed to establish the optimal cut-off points and the
likelihood ratios (LRs) of VEGF between malignant and
non-malignant effusions (Fig. 2).The cut-off used for VEGF in pleural ﬂuid in discriminat-
ing malignant from other groups is 1800 pg/ml with sensitivity
of 95% and speciﬁcity of 96%.
Discussion
In some cases of pleural effusions, the cause might be obvious,
such as pleural effusions associated with Congestive heart fail-
ure or Liver cell failure. In other cases the cause of pleural effu-
sions might not be obvious necessitating extensive diagnostic
procedures in an attempt to identify the cause of effusion [6].
Pleural ﬂuid cytology and blind pleural biopsy are the methods
most commonly used but are inadequate procedures for the
diagnosis. In some studies, blind pleural biopsy has been
reported to be inadequate in up to 40% of the patients [7].
This situation puts forward the need for a different method
directed to pleural ﬂuid. Certain molecular markers, if proven
to be sensitive and speciﬁc enough, can help the physician de-
cide whether the patient should have further investigation or
not to diagnose a suspected malignancy, i.e. open pleural
biopsy (VATS, mini-thoracotomy). Among these biomarkers,
insulin growth factor, hepatocyte growth factor and Simian
Virus-40 have been proven to play an important role in the
development and progression of malignant mesothelioma [8].
VEGF is another molecule that has been expressed, and has
been taking an important role in the development of malignant
pleural effusion. Although some authors have claimed that
lymphatic blockage resulting from tumor cells is the main
contributing factor for the development of malignant pleural
effusion, others have accused VEGF at the ﬁrst place [9].
In our study Mean value of pleural ﬂuid VEGF for the
malignant group was 3208 pg/mL. Lim et al. [10] found that
the mean value of pleural ﬂuid VEGF for the malignant group
was 2418 pg/mL. Cheng et al. [11] found that the median level
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4097 pg/mL. Ziora et al. [12], found the median VEGF level
in malignant pleural effusion 2450 pg/ml and this was
signiﬁcantly higher than tuberculous pleural effusion (median
994 pg/ml), and transudative pleural effusion.
These results are also in agreement with Yanagawa et al.
[13] who reported that exudative pleural effusions contained
signiﬁcantly higher amounts of VEGF than transudative
pleural effusions, and that among exudative pleural
effusions, levels of VEGF in malignant pleural effusion
2292 ± 782 pg/mL were signiﬁcantly higher than those of
benign exudative pleural effusions 522 ± 245 pg/mL. Dalokay
et al. [14], reported that the mean level of VEGF in patients
with malignant pleural effusions (2117 ± 118 pg/ml) was
signiﬁcantly higher than that of non-malignant (732 ±
305 pg/ml) pleural effusions (p< 0.001).
Sack et al. [15] found that the ratio for pleural ﬂuid
VEGF/serum VEGF in malignant pleural effusion was mean
value 7.6 ± 1.8, for empyema was mean value 4.46 ± 11.38,
for tuberculous effusion was mean value 2.93 ± 3.46 and the
transudative group showed mean value of 0.849 ± 1.32 and
this is consistent with Table 6.
By using the ROC (Receiver Operating Characteristic)
analysis, Fig. 2 this study shows that at a cut-off value of
1800 pg/ml, pleural ﬂuid VEGF has a sensitivity of 95% and
speciﬁcity of 96% in diagnosis of malignant pleural effusion.
Momi et al. [16], found that the sensitivity and speciﬁcity of
pleural ﬂuid VEGF (at cut-off value 2000 pg/ml) in the diagno-
sis of malignant pleural effusion were 100% and 84% respec-
tively while Liu et al. [17] reported that pleural ﬂuid VEGF
in diagnosis of malignant pleural effusion has 91.4% sensitiv-
ity and 90% speciﬁcity. Shu et al. [18] show sensitivity and
speciﬁcity of VEGF in PE of 47% and of 96% (cut-off of
959 pg/ml). In the literature the data are variable and this
can be explained by different cut-off points considered.
In conclusion, VEGF is highest in malignant pleural effu-
sion. The differential diagnosis of effusions might be further
improved by including vascular endothelial growth factor con-
centrations into the diagnostic armamentarium available to the
clinician. If VEGF is important for pleural ﬂuid accumulation
then novel antiVEGF therapies could directly inﬂuence the
rapidity of pleural ﬂuid accumulation in addition to possessing
an anti-tumor effect.
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